Search

everythinglearnresearchcommunity

for

Search:↓

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Pexidartinib often causes liver issues and fatigue, especially in women.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

A reliable method was created to measure dutasteride and related molecules in capsules.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Oral bicalutamide is safe and effective for female hair loss.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

QLT0267 stops hair follicle cell growth and movement.

The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.